scholarly journals Bowel movement frequency in late-life and substantia nigra neuron density at death

2008 ◽  
Vol 24 (3) ◽  
pp. 371-376 ◽  
Author(s):  
Helen Petrovitch ◽  
Robert D. Abbott ◽  
G. Webster Ross ◽  
James Nelson ◽  
Kamal H. Masaki ◽  
...  
Keyword(s):  
Substantia Nigra ◽  
Bowel Movement ◽  
Late Life ◽  
Neuron Density ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Substantia Nigra Neuron

Bowel movement frequency in late-life and incidental Lewy bodies

2007 ◽  
Vol 22 (11) ◽  
pp. 1581-1586 ◽  
Author(s):  
Robert D. Abbott ◽  
G. Webster Ross ◽  
Helen Petrovitch ◽  
Caroline M. Tanner ◽  
Daron G. Davis ◽  
...  
Keyword(s):  
Bowel Movement ◽  
Lewy Bodies ◽  
Late Life ◽  
Movement Frequency ◽  
Bowel Movement Frequency

W1903 Prevalence and Factors Associated With Low Bowel Movement Frequency in Hospitalized Older Adults

2010 ◽  
Vol 138 (5) ◽  
pp. S-762-S-763
Author(s):  
Jen-Tzer Gau ◽  
Michael Finamore ◽  
Steve Walston ◽  
Victor Heh ◽  
Tzu-Cheg Kao
Keyword(s):  
Older Adults ◽  
Bowel Movement ◽  
Factors Associated ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Hospitalized Older Adults

Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacteria infantis 35624

2005 ◽  
Vol 100 ◽  
pp. S326
Author(s):  
E. M. Quigley ◽  
P. J. Whorwell ◽  
L. Altringer ◽  
J. Morel ◽  
L. OʼMahony ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bowel Movement ◽  
The Novel ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Impact of Methadone Dose and Baseline Bowel Movement Frequency on Efficacy of Lubiprostone for Opioid-Induced Constipation

2014 ◽  
Vol 109 ◽  
pp. S532-S533 ◽  
Author(s):  
Byron Cryer ◽  
Peter Lichtlen ◽  
Martin Wang ◽  
Taryn Losch-Beridon
Keyword(s):  
Bowel Movement ◽  
Methadone Dose ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Evaluation of disease-specific and functional symptom items on carcinoid tumor patients treated with telotristat ethyl.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 427-427
Author(s):  
Stacie Hudgens ◽  
Pablo Lapuerta ◽  
Lysbeth Floden
Keyword(s):  
Quality Of Life ◽  
Weight Gain ◽  
Carcinoid Syndrome ◽  
Bowel Movement ◽  
Phase Iii ◽  
Odds Ratios ◽  
European Organisation ◽  
Movement Frequency ◽  
Bowel Movement Frequency

427 Background: Within the pivotal, phase III TELESTAR trial, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo ( P < 0.001) (NCT01677910). Assessing patient-related outcomes can help understand the impact of changes in BM frequency on patient lives. An analysis was done to determine whether individual items on patient-reported outcome measures show relevant patterns over the course of treatment for patients with carcinoid syndrome (CS). Methods: The TELESTAR study was a phase III, double-blind, parallel-group, randomized, placebo-controlled study comparing placebo (PBO) to telotristat ethyl (TE) in 135 patients with Carcinoid Syndrome (CS). Clinical quality of life (QoL) measurements included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer (EORTC) GI.NET21 scales. Analyses on identified individual gastrointestinal (GI) symptom and role function items were conducted using longitudinal generalized estimation equations (GEE; reference=PBO) to characterize the likelihood of a 1-grade categorical improvement (e.g., improvement by one category on the verbal response scale). Forest plots of odds ratios (OR) and associated confidence intervals (CI) on individual items are presented. Results: At week 12, the likelihood of patients experiencing a 1-grade improvement on most GI symptoms were equivalent (OR approx. 1.0). The highest odds ratios observed with TE were for improvement in diarrhea (OR=1.86, CI=0.848-4.090) and a reduction in weight bother (OR=2.95, CI=0.713-12.199), in parallel to TELESTAR results for bowel movement frequency reduction and weight gain. Interference with daily activities (IADL) and limitations in doing work demonstrated similar outcomes (IADL OR=1.63, CI=0.617,4.288; Work OR=1.97, CI=0.722,5.376). Conclusions: The overall pattern of item level change on telotristat suggested clinical relevance for bowel movement frequency reduction and weight gain, and it was consistent with symptomatic and functional benefit in CS. Clinical trial information: NCT01677910.

scholarly journals Parkinson’s Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish

2020 ◽  
Vol 54 (5) ◽  
pp. 392-397
Author(s):  
Michael D.F. Goldenberg ◽  
Xuemei Huang ◽  
Honglei Chen ◽  
Lan Kong ◽  
Teodor T. Postolache ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Daytime Sleepiness ◽  
Bowel Movement ◽  
Motor Symptoms ◽  
Nonmotor Symptoms ◽  
Case Identification ◽  
Movement Frequency ◽  
Bowel Movements ◽  
Bowel Movement Frequency

<b><i>Introduction:</i></b> Previous research has suggested that the Amish may experience a relatively high prevalence of Parkinson’s disease (PD) and/or parkinsonian motor signs. <b><i>Methods:</i></b> In a large sample from the Amish community in Lancaster County, Pennsylvania, age ≥18 years, we assessed the prevalence of self-reported PD diagnosis. For those without self-reported PD diagnosis, we assessed the frequency of PD-related motor symptoms using a 9-item questionnaire that was designed by the PD Epidemiology Research Group. Lastly, we queried study participants for the presence of 2 nonmotor symptoms that have been commonly linked to PD: bowel movement frequency and daytime sleepiness. <b><i>Results:</i></b> Among 2,025 subjects who answered the PD questionnaire, 430 were older than 60 years. Of 430 participants ≥60 years, 5 (1.2%) reported a PD diagnosis. Of those without a PD diagnosis, 10.5% reported ≥1 and 1.2% ≥ 4 motor symptoms for the 9-item PD screening questionnaire. Of the 3,789 subjects who answered the question about bowel movement frequency, 0.7% reported ≤3 bowel movements per week. Among 1,710 subjects who answered the question about daytime sleepiness, 8.1% of the participants reported “always” sleepy during the day. <b><i>Discussion:</i></b> These data neither support a markedly higher PD prevalence in the older Lancaster Amish nor do they show dramatically higher motor and/or selected nonmotor symptoms than the general population. Future studies that employ more rigorous procedures for case identification and PD-specific preclinical symptoms/tests are needed to determine the potential differences and similarities among different Amish populations and between Amish and non-Amish populations.

Abstract 839: Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men

2021 ◽  
Author(s):  
Lu Long ◽  
Xing Liu ◽  
Lina Jin ◽  
Tracey Simon ◽  
Wenjie Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bowel Movement ◽  
Laxative Use ◽  
Movement Frequency ◽  
Bowel Movement Frequency

The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial*

2014 ◽  
Vol 23 (4) ◽  
pp. 387-391 ◽  
Author(s):  
Veronica Ojetti ◽  
Gianluca Ianiro ◽  
Annalisa Tortora ◽  
Giovanna D‘Angelo ◽  
Teresa Antonella Di Rienzo ◽  
...  
Keyword(s):  
Bowel Movement ◽  
Lactobacillus Reuteri ◽  
Controlled Trial ◽  
Functional Constipation ◽  
Stool Consistency ◽  
Double Blind ◽  
Movement Frequency ◽  
Bowel Movements ◽  
Bowel Movement Frequency ◽  
The Mean

Background & Aims: There is a growing interest for the use of probiotics for chronic constipation. A recent randomized controlled trial (RCT) showed a positive effect of Lactobacillus reuteri (L. reuteri) on bowel movement frequency in infants with chronic constipation. The aim of the present study was to evaluate the effects of L. reuteri in adult patients with functional constipation.Methods: A double-blind, placebo RCT was conducted in 40 adults (18M/22F, 35±15 years) affected by functional constipation according to the Rome III criteria. Patients were randomly assigned to receive a supplementation of L. reuteri (DSM 17938), or matching placebo for 4 weeks. The increase of bowel movements/week was the primary outcome, while the improvement of stool consistency was the secondary outcome.Results: At week 4, the mean increase in bowel movements/week was 2.6 (SD±1.14, 95% CI:1.6-3.6) in the L. reuteri group and 1.0 (SD±1. 95% CI:0.12-1.88) in the placebo group (p=0.046). At the end of the treatment, the mean bowel movements/week was 5.28±1.93 in the L. reuteri group and 3.89±1.79 in the placebo group. There was a not significant difference in the stool consistency between the two groups.Conclusions: L. reuteri is more effective than the placebo in improving bowel movement frequency in adult patients with functional constipation as previously demonstrated in children, even if it seems to have no effect on stool consistency.

Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency

Pancreas ◽  
2020 ◽  
Vol 49 (3) ◽  
pp. 408-412
Author(s):  
Al B. Benson ◽  
Jonathan Strosberg ◽  
Vijay N. Joish ◽  
Samyukta Dharba ◽  
Dipa Sapre ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Bowel Movement ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Clinical Benefits
Sign in / Sign up

Export Citation Format

Share Document